MedTrace Logo

PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension

NCT02058446 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-11-13

No results posted yet for this study

Summary

The antihypertensive effect of Amlodipine/Valsartan combination has been evaluated in worldwide populations including Asian patients. The study primarily aims to evaluate the effectiveness of Amlodipine/Valsartan combination in patients with essential hypertension in Taiwan using a prospective, open-label, non-randomized approach.

The study also wants to investigate the safety of Amlodipine/Valsartan combination during the 6-week treatment period.

Conditions

  • Essential Hypertension

Interventions

DRUG

Amlodipine/Valsartan

Amlodipine/Valsartan: 5 mg/80 mg

Sponsors & Collaborators

  • TSH Biopharm Corporation Limited

    lead INDUSTRY

Principal Investigators

  • Kuo-Yang Wang, MD, PhD · Taichung Veterans General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02058446 on ClinicalTrials.gov